CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Decitabinedrug
Likely dose
Decitabine 20 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01786343
NCT01786343Phase 2Completed
CompareCT.gov

A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center·interventional·Posted Feb 7, 2013·Updated Apr 15, 2020

In Brief

A Phase 2 clinical trial evaluating Decitabine for Leukemia. Completed, enrolled 74 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML. Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2013
Enrollment StartFeb 5, 2013
Primary CompletionMay 6, 2019
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 13.4 years ago

Interventions

Decitabinedrug

20 mg/m2 by vein daily for either 5 or 10 days.